Enzyme Replacement Therapy Market Report 2026

The enzyme replacement therapy market size has grown strongly in recent years. It will grow from $12.36 billion in 2025 to $13.43 billion in 2026 at a compound annual growth rate (CAGR) of 8.6%. The growth in the historic period can be attributed to growing prevalence of lysosomal storage disorders, advancement in recombinant DNA technology, rising awareness about rare diseases, increasing hospital infrastructure, government initiatives supporting rare disease treatments.

The enzyme replacement therapy market size is expected to see strong growth in the next few years. It will grow to $19.29 billion in 2030 at a compound annual growth rate (CAGR) of 9.5%. The growth in the forecast period can be attributed to expansion of precision medicine, development of novel enzyme formulations, increasing adoption of home infusion therapies, integration of digital health solutions, rising collaborations between biotech companies and research institutes. Major trends in the forecast period include personalized enzyme replacement therapies, expansion of rare disease treatment programs, development of long-acting enzyme formulations, adoption of minimally invasive administration routes, integration of real-world evidence in therapy optimization.

The increasing level of healthcare expenditure is anticipated to drive the expansion of the enzyme replacement therapy (ERT) market in the coming years. Healthcare expenditure represents the total spending on healthcare services, products, and related activities within a healthcare system or economy over a specified period. Enzyme replacement therapy relies heavily on healthcare spending because of the highly specialized and often costly nature of these treatments, particularly in relation to research and development, clinical trials, and extensive testing processes. For example, in June 2025, according to the Centers for Medicare & Medicaid Services, a US-based federal agency, National Health Expenditure increased by 7.5% to $4.9 trillion in 2023, equating to $14,570 per person and accounting for 17.6% of the US gross domestic product. During the same year, hospital expenditures rose by 10.4% to $1.51 trillion, significantly higher than the 3.2% growth recorded in 2022. As a result, rising healthcare expenditures are contributing to the growth of the enzyme replacement therapy market.

Major companies operating in the enzyme replacement therapy market are emphasizing the development of innovative treatment options and securing regulatory approvals for therapies targeting rare diseases such as Pompe disease, in order to address significant unmet medical needs. Pompe disease therapies in the European Union include enzyme replacement treatments designed for adults with late-onset Pompe disease. For instance, in June 2023, Amicus Therapeutics announced the approval and launch of a new Pompe disease therapy in the European Union. This decision was driven by strong clinical data, regulatory backing, and the unmet needs of patients with late-onset Pompe disease. The approved treatment combines Pombiliti (cipaglucosidase alfa) with Opfolda (miglustat) and is indicated as an enzyme replacement therapy for adults affected by this condition.

In July 2024, Crosswalk Therapeutics Inc. acquired Codexis Inc. for an undisclosed amount. Through this acquisition, Crosswalk Therapeutics aims to strengthen its capabilities by incorporating Codexis’ expertise in enzyme engineering, supporting the development and advancement of enzyme-based therapeutic solutions. Codexis Inc. is a US-based company specializing in enzyme engineering and biocatalyst development.

Major companies operating in the enzyme replacement therapy market are Biomarin Pharmaceutical Inc., Leadiant Biosciences Inc., Pfizer Inc., Sanofi S.A., AbbVie Inc., Alexion Pharmaceuticals Inc., Recordati Rare Diseases Inc., JCR Pharmaceuticals Co. Ltd., Horizon Pharma Public Limited Company, Protalix Biotherapeutics Ltd., Amicus Therapeutics Inc., AstraZeneca plc, Novartis AG, Roche Holding AG, GlaxoSmithKline plc, Merck & Co. Inc., Eli Lilly and Company, Bristol-Myers Squibb Company, Retrophin Inc., Abeona Therapeutics Inc., Orchard Therapeutics plc, Ultragenyx Pharmaceutical Inc.

North America was the largest region in the enzyme replacement therapy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the global enzyme replacement therapy market report during the forecast period. The regions covered in the enzyme replacement therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the enzyme replacement therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have affected the enzyme replacement therapy market by increasing import costs for biologics, enzymes, and specialized manufacturing equipment. The parenteral administration segment and high-cost enzyme types such as agalsidase beta and galsulfase are particularly impacted, with North America and Europe facing higher price pressures due to reliance on imported enzymes. While tariffs have led to cost challenges, they are also encouraging local manufacturing initiatives and strategic partnerships to mitigate dependency on foreign suppliers, fostering innovation in cost-efficient enzyme therapies.

The enzyme replacement therapy market research report is one of a series of new reports that provides enzyme replacement therapy market statistics, including enzyme replacement therapy industry global market size, regional shares, competitors with a enzyme replacement therapy market share, detailed enzyme replacement therapy market segments, market trends and opportunities, and any further data you may need to thrive in the enzyme replacement therapy industry. This enzyme replacement therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Enzyme replacement therapy (ERT) is a form of medical treatment in which patients with chronic conditions caused by deficient or malfunctioning enzymes are provided with replacement enzymes. By supplying these enzymes, the body is able to carry out biological processes that are otherwise impaired due to the deficiency. This therapy is particularly effective in normalizing urinary glycosaminoglycan (GAG) levels and enhancing liver and spleen growth.

The main types of enzymes used in enzyme replacement therapy include agalsidase alfa, agalsidase beta, galsulfase, and other enzyme types, which are used in the treatment of conditions such as Gaucher disease, Pompe disease, Fabry disease, and others. Agalsidase alfa is a recombinant human alpha-galactosidase used as an enzyme replacement therapy for the treatment of Fabry disease. It has a long half-life and a wide therapeutic range. Patients should be informed about the potential for infusion-related reactions and hypersensitivity. Agalsidase alfa supports enzyme replacement therapy by helping manage Fabry disease. Enzyme replacement therapy is administered through oral and parenteral routes and is used by hospitals, infusion centers, and other healthcare settings.

The enzyme replacement therapy market includes revenues earned by entities by providing Sebelipase alfa, Elosulfase alfa, Idursulfase, AL glucosidase alfa and Alpha1-Proteinase inhibitor enzyme replacement therapies. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.